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A B S T R A C T
Rich evidence has highlighted that stimulation of g-amino-butyric acid (GABA)B receptors increases the
occurrence of spike-and-wave discharges (SWDs), the electroencephalographic (EEG) landmark of
absence epilepsy (AE). Recent ﬁndings suggest that the outcomes of GABAB activation in vivo are
contingent on the chemical characteristics of the agonist. In particular, the endogenous ligand g-
hydroxybutyrate (GHB) and its precursor g-butyro-lactone (GBL) have been shown to elicit different
effects than the prototypical GABAB agonist baclofen. In view of these premises, the present study was
aimed at the characterization of the effects of baclofen (0.5–10 mg/kg, i.p.) and GBL (5–100 mg/kg, i.p.)
on the spontaneous SWDs and locomotor activity of DBA/2J mice.
While both baclofen and GBL dose-dependently increased SWDs episodes, high doses of the latter
(100 mg/kg, i.p.) reduced the occurrence of these phenomena and increased the number of isolated
spikes. Interestingly, both compounds elicited a dose-dependent reduction of locomotor activity, in
comparison with their vehicle-treated controls. The GABAB selective antagonist, SCH50911 (50 mg/kg,
i.p.), reversed the changes in SWD occurrence and locomotion induced by baclofen and GBL, but failed to
elicit intrinsic effects on either paradigm. These results indicate that GABAB receptor signaling might
exert differential effects on SWDs in DBA/2J mice.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Absence epilepsy (AE) is an idiopathic, non-convulsive epilepsy
characterized by brief, sudden interruptions of consciousness and
minor automatisms.1 Such episodes, generally benign and self-
limited, are concomitant with distinct electrocorticographic
(ECoG) alterations, consisting in bilateral synchronous bursts of
spike–wave discharges (SWDs) at typical frequency around 3–
4 Hz.2 Although the molecular bases of AE are largely elusive, the
wealth of evidence supports the involvement of g-aminobutyric
acid (GABA) transmission in their pathophysiology. In particular,
several studies suggest that GABAB receptor activation may
exacerbate AE in several animal models.3 Recent studies have* Corresponding authors at: Department of Neurological and Cardiovascular
Sciences, University of Cagliari, Policlinico Universitario, S.S. 554 Km 4.500, 09042
Monserrato (CA), Italy. Tel.: +39 070 51096191; fax: +39 070 51096032.
E-mail addresses: bortolat@usc.edu (M. Bortolato), marrosu@unica.it
(F. Marrosu).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.02.007suggested that abnormalities in GABAB receptor signaling may
account for several phenotypical alterations exhibited by DBA/2J
mice,4,5 a strain exhibiting EEG patterns reminiscent of those
observed in AE.5,6 Capitalizing on this background, we addressed
the present study to investigate the role of GABAB receptors in the
expression of SWDs in DBA/2J mice.
Recent lines of evidence suggest that the in vivo outcomes of
GABAB activation are contingent on the chemical characteristics of
the agonist. In particular, the endogenous ligand g-hydroxybuty-
rate (GHB) and its precursor g-butyro-lactone (GBL) have been
shown to elicit GABAB-dependent behavioral effects which differ
from those mediated by the prototypical agonists of this
receptor,7–9 such as baclofen.
Although both GHB and baclofen have been shown to induce, in
both humans and laboratory animals, EEG abnormalities similar to
those associated with AE,10,11 the speciﬁc impact of each agonist
has not been compared to date. This premise prompted us to test
the EEG response of DBA2/J mice to baclofen and GBL, in
comparison with the locomotor alterations induced by both drugs.
The latter compound was preferred to GHB on account of itsvier Ltd. All rights reserved.
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ability to cross the blood–brain barrier12; second, it is inherently
inactive and rapidly converted to GHB after parenteral adminis-
tration13; ﬁnally, it shows a better dissociation between EEG
abnormalities and alterations of thermoregulation than its
metabolite.14
To understand whether the differences between baclofen and
GBL may be actually mediated by GABAB receptors, the effects of
the two compounds were also studied in presence of a GABAB
selective antagonist, SCH50911.
2. Materials and methods
2.1. Animals
Juvenile (4–5 weeks old) male DBA/2J mice (Harlan, Como,
Italy) (n = 131; weight: 25–30 g each) were housed four per cage
under a 12 h light/dark cycle (light on at 8:00 AM), in conditions of
constant temperature (21  2 8C) and humidity (60%), with food and
water ad libitum. All experimental procedures were approved by the
local ethical committee and conducted in conformity with the
University of Cagliari guidelines. The experimental preparation
followed the methods previously described.5 Brieﬂy, mice were
anesthetized and placed in a stereotaxic apparatus (David Kopf, mod.
900). Each skull was exposed and perforated in four points, located
above both sensorimotor cortices (FPr and FPl), 0.5 mmanterior to the
bregma (Cz), and over the cerebellum (G2). A four-pin male socket
was positioned into the holes, secured to the skull with epoxy resin
and covered with acrylic cement to improve retention.
2.2. Drugs
The following drugs were used in this study: GABAB receptor
agonists baclofen and g-butyro-lactone (GBL), as well as GABAB
antagonist SCH50911 (Tocris Cookson, UK). All drugs were
dissolved in saline 0.9% and administered intraperitoneally (i.p.)
in an injection volume of 10 ml/kg. The dose ranges of baclofen and
GBL were selected so as to have similar efﬁcacy, based on the
comparison of their ED50 values
8 and on preliminary observations
by our group.
2.3. EEG recordings
EEG recordings were acquired on a portable EEG polygraph
(BQS 98 System Micromed, Mogliano Veneto, Italy), and the
Electrode impedancewasmaintained at<5 kV. Digital EEG signals
were ﬁltered with elliptical ﬁlter banks to obtain the optimal
resolution of broadband parameters. Given that synchronization
analysis requires a zero-phase ﬁltering distortion, data were
further processed by forward–backward ﬁltering.15 The off-line
SWDs analysis was accomplished separately by trained research-
ers blinded to this experimental phase of the study. In addition to
visual inspection, SWDs morphology was assessed by means of a
customized algorithm aimed at detecting signiﬁcant variations
occurring under a pre-settled threshold, based on the analysis of
the fractal dimension of the EEG signal.16
DBA/2J mice exhibited an EEG pattern with 12–18 Hz low-
medium voltage background activity mixed with 6–12 Hz high-
voltage SWDs events. Tomaintain normality and homoscedasticity
criteria in the sampled population, experiments were performed
on the basis of SWD event frequency in the baseline EEG recording
by selecting animals displaying between 6 and 25 SWDs/30 min
(with a median value of 13 in the overall tested population) while
mice showing very low or very high number of SWDs (more than
two standard deviations above or below group mean values) were
excluded from the study. Each treatment group consisted of 5–7animals, and each animal was injected with only one dose
throughout the study. Recordings started between 8 and
10:30 AM, and were analyzed in two blocks, respectively before
and after drug administration. The ﬁrst block, lasted 60 min (two
30-min intervals) and was used to monitor the baseline conditions
of each animal. In this phase of EEG recording, DBA/2J mice
exhibited characteristic spontaneous short-lasting spiking activity
bursts (4–12 s duration and 250–550mV amplitude), super-
imposed to baseline activity of 50–120mV EEG rhythms.
The second block lasted 90–150 min (three to ﬁve 30-min
intervals) and was used to assess the effects of the treatment. SWD
analysis was based on their number (calculated as the average
number of events occurring in a 30-min interval) and mean
duration for pre- and post-injection blocks were calculated.
Episodes of drowsiness and sleep were discarded, as previous
studies in other rodent models of AE showed relevant SWDs
variations during sleep.17
2.4. Locomotor activity
We tested the impact of GABAB ligands on the locomotor
activity in a different group of DBA/2J mice. The motility cages
(Omnitech Digiscan Animal Activity Monitor, Columbus, OH, USA)
featured 2 sets of 16 photocells located at right angles to each
other, projecting horizontal infrared beams 2.5 cm apart above the
cage ﬂoor. After a 30-min acclimatization period in the apparatus,
each animalwas injected and its locomotor activitywas studied for
further 90 min. Locomotion was measured with the horizontal
activity counts in 10-min intervals.
2.5. Statistical analyses
Number andmean duration of SWDs were analyzed by 2-factor
ANOVAs, with treatment dose as an independent factor and blocks
(pre- and post-injection) as repeatedmeasures. Locomotor activity
was analyzed by 2-factor ANOVAs, with dose as independent factor
and time (consecutive 10-min intervals). Post hoc comparisons
were performed with Tukey’s test. Alpha was set at p < 0.05.
3. Results
3.1. Effects of baclofen on SWD
In the ﬁrst experiment (Fig. 1), the effects of baclofen (0.5–
10 mg/kg, i.p.; n = 5–7/group) on SWD number and mean duration
were tested and compared with both vehicle-treated mice and
their individual baseline values. Baclofen was found to exert a
signiﬁcant main effect on SWDs occurrence [F(1,29) = 38.44,
p < 0.001]. The analysis of dose  block interactions also revealed
a signiﬁcant effect [F(5,29) = 10.63, p < 0.001]. Post hoc compar-
isons further established that the doses of 2.5, 5 and 10 produced a
signiﬁcant increase in comparison to their baseline and to vehicle-
treated subjects. Conversely, baclofen did not produce any
signiﬁcant change in SWD duration (Fig. 1d) at any dose tested.
No difference in baseline SWD number or duration was found.
3.2. Effects of baclofen on locomotor activity
As changes in the number of SWDs may reﬂect behavioral
alterations (suchasprofound sedation),weevaluated thebehavioral
impact of baclofen (2.5–10 mg/kg, i.p.) on the motor activity of a
different group of DBA/2J mice (n = 5/group). The evaluation of the
effects of baclofen (2.5–10 mg/kg, i.p.) on locomotor activity
revealed a main dose effect [F(3,16) = 5.91, p< 0.01], which was
found to reﬂect a signiﬁcant difference between the animals treated
withvehicle and those injectedwith the10 mg/kgdoseof theGABAB
Fig. 1. Baclofen increases number andmean duration of spike-and-wave discharges
(SWDs), but does not affect their morphology. EEG patterns before (a) and after (b)
baclofen treatment (5 mg/kg, i.p.). (c) Number and (d) mean duration of SWDs after
different baclofen doses (0.5–10 mg/kg, i.p.). Values are expressed as mean
SWDs  S.E.M. White columns: baseline SWDs; black columns: SWDs after baclofen
injection; Baclofen doses are indicated in mg/kg (i.p.). VEH, vehicle. *p < 0.05,
**p < 0.01, in comparison to relative baseline. n = 5–7 for each group. For further
details, see text.
Fig. 2. Baclofen reduces locomotor activity of DBA/2J mice in a dose-dependent
fashion. Values are expressed as mean  S.E.M. Baclofen doses are indicated inmg/kg
(i.p.). VEH, vehicle. *p < 0.05 in comparison to VEH-treated mice in the same time
point. n = 5 for each group. For further details, see text.
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effect for time [F(9,144) = 55.09, p< 0.001] and a signiﬁcant
dose time interaction [F(27,144) = 2.08, p < 0.01]. Post hoc
scrutiny of this effect revealed that the 10 mg/kg dose of baclofen
induced a signiﬁcant reduction in activity at 30 and 40 min after
injection (Fig. 2). None of the other doses triggered signiﬁcant
alterations in locomotor activity in comparison with vehicle-
injected animals.
3.3. Effects of GBL on SWD
The third experimentwas designed to test the effect of different
GBL doses (5–100 mg/kg, i.p.; n = 5–7/group) on SWD number and
mean duration. GBL signiﬁcantly increased SWD number
[F(1,23) = 20.09, p < 0.001]. Further analysis revealed that such
effect was dose-dependent [F(4,23) = 7.50, p < 0.001] and signiﬁ-
cant at the intraperitoneal doses of 50 (p < 0.05) and 100 mg/kgFig. 3.GBLmodiﬁes the number, mean duration andmorphology of spike-and-wave disc
(c) Number and (d) mean duration of SWDs after different GBL doses (5–100 mg/kg, i.p.)
columns: SWDs after GBL injection; GBL doses are indicated inmg/kg (i.p.). VEH, vehicle. *p <
details, see text.(p < 0.01) (Tukey’s test) (Fig. 3). Interestingly, GBL effects on SWD
duration produced a reduction close to signiﬁcance threshold
[F(1,23) = 4.00, p = 0.056]. Further analysis revealed that such
effect was signiﬁcant at the dose of 100 mg/kg (i.p.) [dose  block
interaction: F(4,23) = 7.50, p < 0.001, p < 0.01 for 100 mg/kg dose,
Tukey’s test]. No difference in baseline SWD number or duration
was found.
3.4. Effects of GBL on locomotor activity
We then tested the impact of GBL (50–100 mg/kg, i.p.; n = 5/
group) on locomotor activity, with a design mirroring the
experiment on baclofen. ANOVA detected main effects for both
treatment dose [F(2,12) = 4.08, p < 0.05 for comparison between
vehicle and GBL 100 mg/kg] and time [F(9,108) = 22.33, p < 0.001],
as well as a signiﬁcant dose  time interaction [F(18,108) = 4.91,
p < 0.001]. As shown in Fig. 4, post hoc comparisons revealed that
the highest dose of GBL caused a signiﬁcant reduction of locomotor
activity at 20 and 30 min after administration (p < 0.05) in
comparison to vehicle-treated controls.harges (SWDs). EEG patterns before (a) and after (b) GBL treatment (100 mg/kg, i.p.).
. Values are expressed as mean SWDs  S.E.M. White columns: baseline SWDs; black
0.05, **p < 0.01, in comparison to relative baseline. n = 5–7 for each group. For further
Fig. 4. GBL reduces locomotor activity of DBA/2J mice in a dose-dependent fashion.
Values are expressed as mean  S.E.M. Baclofen doses are indicated in mg/kg (i.p.).
VEH, vehicle. *p < 0.05 in comparison to VEH-treatedmice in the same time point. n = 5
for each group. For further details, see text.
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In the next experiment, we veriﬁed whether the variations
in SWDs and EEG produced by baclofen (5 mg/kg, i.p.) and
GBL (100 mg/kg, i.p.) were reversed by pretreatment with
SCH50911 (50 mg/kg, i.p.) (Fig. 5). Indeed, ANOVA revealed that
SCH50911 did not elicit any effect in either experiment in
comparison with its vehicle [F(1,11) = 3.13, NS; F(1,12) = 3.87,
NS], but reversed the increase in SWD number induced by both
baclofen [F(1,11) = 25.85, p < 0.001; Tukey: p < 0.01 for SCH vs
VEH comparison] and GBL [F(1,12) = 23.94, p < 0.001; Tukey:
p < 0.01 for SCH vs VEH comparison]. SCH50911 also prevented
GBL from reducing SWD mean duration [F(1,12) = 4.97, p < 0.05],
suggesting that all the GBL-mediated variations are due to GABAB
receptor activation.
In a separate experiment, we veriﬁed the impact of SCH50911
on the locomotor effects of baclofen (10 mg/kg, i.p.) and GBLFig. 5. SCH50911 reverses both baclofen (BAC)- and GBL-induced SWD
modiﬁcations in DBA/2J mice. (a) Number and (b) mean duration of SWDs after
SCH50911 (50 mg/kg, i.p.) in combinationwith BAC (5 mg/kg, i.p.), GBL (100 mg/kg,
i.p.) or their vehicle (VEH). Values are expressed as mean SWDs  S.E.M. White
columns: baseline SWDs; black columns: SWDs after treatment. **p < 0.01, in
comparison to relative baseline; ##p < 0.01 in comparison to VEH-treated animals.
n = 8–10 for each group. For further details, see text.(100 mg/kg, i.p.). As expected, the GABAB antagonist did not
inherently modify the locomotor activity, and completely coun-
tered the effects of both agents (data not shown).
4. Discussion
The main result of the present study is that both baclofen and
GBL, two GABAB receptor agonists, signiﬁcantly increase SWD
expression in DBA/2J mice. Notably, while baclofen and low
doses of GBL enhanced the occurrence of SWDs without
affecting their duration, high doses of GBL shortened the
average duration of these phenomena. The selective GABAB
antagonist SCH50911 prevented the increase in SWD number
induced by baclofen and GBL, conﬁrming that both compounds
produced their effects through activation of GABAB receptors.
Furthermore, the intermediate doses of baclofen (2.5–5 mg/kg)
and GBL (50 mg/kg) increased the number of SWDs without
eliciting any signiﬁcant effect on locomotion, suggesting that the
reported alterations in SWD manifestations are not completely
secondary to behavioral changes.
Our ﬁndings are consistent with previous evidence, highlight-
ing a key role for GABAB receptors in SWDs modulation. Indeed,
GABAB receptor activation exacerbates SWDs in AE rodent
models.18,19 The different impact on SWD modulation elicited
by equipotent doses of baclofen and GBL is also in line with recent
lines of evidence documenting that their effects, albeit both
mediated by GABAB receptors, are underpinned by partially
divergent mechanisms.7–9 The distinctive effects of the two GABAB
agonists have been posited to reﬂect separate contributions from
different receptor subpopulations.8,9 Although the evidence on
GABAB subtypes is still inconclusive,
22 converging lines of research
support their existence and indicate that they may exert different
roles in relation to their different regional distribution and
intracellular segregation.23–26 Thus, variations in afﬁnity for
different isoforms of GABAB subunits (or their combination)
may condition the outcomes of different GABAB ligands in AE
murine models.27 This conceptual framework may also help
understand the different proﬁle of Fos expression enkindled by
GHB and baclofen.28
In a well-validated AE model, lethargic (lh/lh) mice, GABAB
receptors modulate absence expression based on their regional-
speciﬁc sensitivity in thalamo-cortical nuclei, as well as ventral
thalamic nuclei and nucleus reuniens.29 Indeed, the effects of high
GBL doses on SWD duration might also indicate a preferential
action of this compound on cortical networks, as suggested by
previous studies.25,30 Conversely, baclofen increased SWDs with-
out altering them, suggesting that this compound may activate
mainly thalamo-cortical GABAB receptors.
The functional divergence between GHB and baclofen has been
suggested to reﬂect speciﬁc interactions between speciﬁc GABAB
receptor variants and the N-methyl-D-aspartate (NMDA) subtype
of glutamate receptors.31 This possibility is particularly intriguing,
in view of the role of NMDA receptors in the initiation and
maintenance of SWD,32–34 as well as the altered responsiveness of
NMDA receptors in DBA/2J mice.35
An alternative possibility to account for the different effects of
baclofen and GBL may reﬂect the speciﬁc contribution of GHB on
its own receptors,36,37 which may in turn modulate GABA release
and alter the effects of GABAB receptor activation.
38
The behavioral effects of baclofen and GBL on spontaneous
locomotor activity followed a typical dose- and time-dependent
fashion, with a substantially equivalent pattern in comparison to
vehicle-treated controls. The shorter time of maximal action of
GBL (20–40 min) in comparison to baclofen (30–50) reﬂects
previous observations on the behavioral impact of these two
compounds8 and is likely to signify GHB’s brief half-life.39 The
M. Bortolato et al. / Seizure 19 (2010) 226–231230hypomotility observed in this study is in keeping with previous
results on the effects of both GABAB agonists.
40,41 It is worth
noting the dosages of GBL and baclofen have been shown to be in a
cataleptogenic range in mice,8 suggesting that the near-total lack
of spontaneous activity induced by both agents may have
reﬂected extrapyramidal deﬁcits, plausibly due to the impinge-
ment of common mechanisms.
Our experiments have shown that the proﬁle of SWD
modulation by GABAB ligands in DBA/2J exhibits a number of
atypical features. Firstly, GABAB agonists increased only the
number, but not the duration, of SWD bursts.42 Secondly,
SCH50911 did not suppress SWDs in DBA/2J mice. Particularly
this last ﬁnding is at variance with a large body of evidence
documenting that GABAB blockade reduces AE manifestations and
SWDs in AE models.43–48 By deﬁnition, the intrinsic effects of a
receptor antagonist reﬂect a tone of the endogenous activator;
therefore, the lack of effect of SCH50911 in DBA/2J mice is likely to
indicate that, unlike other AEmodels, these animalsmay not have a
physiological ‘‘GABAB tone’’. While the present study cannot help
identify the mechanisms underpinning such a critical difference, it
is tempting to speculate that this phenomenon may be connected
to our previous ﬁnding of a reduced expression of GABAB receptor
in the cortex.4 Of note, this evidence is in seemingly striking
contrast with the up-regulation of GABAB receptors in other
models of AE.25 Further studies are warranted to establish the
speciﬁc role of GABAB receptors in the circuitry underpinning SWD
in DBA/2J mice and the functional valence of the variations in
GABAB receptors in this strain.
Irrespective of these considerations, the present ﬁndings on
DBA/2J mice warrant further studies on the role of GABAB
receptor in SWD modulation, and suggest that distinctive
actions on GABAB signaling might differentially regulate the
expression of SWDs.
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